Source: Inside Precision Medicine, June 2025
A team of researchers at NYU Langone Health and the Perlmutter Cancer Center has identified a potential therapeutic strategy for melanoma patients whose tumors harbor mutations in the neurofibromin 1 (NF1) gene and who do not respond to current immunotherapy treatments. The study, published in Cancer Research, showed that EGFR inhibitor drugs, already approved for the treatment of head and neck, lung, and colorectal cancers, could be an effective treatment option for this melanoma subtype.
“There is a pressing need for new drug therapies for melanoma patients with neurofibromin 1 mutations that do not respond to the latest immunotherapy, and for which there are no subsequent effective treatment options,” said study lead author Milad Ibrahim, PhD, a postdoctoral fellow in the lab of Iman Osman, MD, at NYU Grossman School of Medicine.